New transplant combo aims to outsmart relapsed leukemia

NCT ID NCT07572695

Not yet recruiting Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a stem cell transplant from a half-matched donor (haploidentical) combined with drugs to prevent the cancer from coming back. It includes 40 adults aged 18-65 with active AML that has returned or not responded to treatment. The goal is to see if this approach can reduce relapse and improve survival over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: haploidentical stem cell transplant with targeted drugs and post-transplant maintenance
What this could lead to: If successful, this approach could offer a better chance of long-term survival for people with hard-to-treat AML who have few options left.
What could go wrong: This is a small, early observational study (40 people) at one center. The transplant carries serious risks like graft-versus-host disease and infection, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML, RELAPSED/REFRACTORY RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.